MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
PARP inhibition in cancer therapy
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,206 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,206 works in the cohort · of 4,299,418page 17 of 25

Labels cover 6 of 1,206 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,206 of 1,206 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer (EC) in DUO-E: Results by <i>BRCA1</i>/<i>BRCA2</i> mutation (BRCAm) status.
Els Van Nieuwenhuysen, Jean‐François Baurain, Hye Sook Chon, Jessica Thomes Pepin, Michael J. Sundborg, Michael A. Gold +14 more
2024· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affno abstractunlabeled
68TiP KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC
Shigehira Saji, Antonio Llombart‐Cussac, Fabrice André, Mark E. Robson, Nadia Harbeck, Peter Schmid +8 more
2020· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affunlabeled
Evaluating Parp1 domains as gossypol targets
Scott Gross, E. Yu. Kotova, N. V. Maluchenko, John M. Pascal, Vasily M. Studitsky
2016· article· en· Moscow University Biological Sciences Bulletin· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affunlabeled
Exploration of circulating tumor cell (CTC) conversion and CTC0 as prognostic biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Steven Yip, Karim Fizazi, Douglas Laird, Nobuaki Matsubara, Arun Azad, Jae Young Joung +9 more
2024· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affno abstractunlabeled
Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the Phase III SOLO1 trial
Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, B-G. Kim, Ana Oaknin, Michael Friedländer +15 more
2019· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affunlabeled
With Our Powers Combined
Lawrence Kasherman, Katherine Karakasis, Amit M. Oza
2021· review· en· The Cancer Journal· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affno abstractunlabeled
Poly (ADP Ribose) Polymerase Inhibitors for Cancer
Lynette M. Sholl, Diana Mandelker, Tracy Stockley
2020· article· en· Journal of Molecular Diagnostics· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affunlabeled
A randomized phase II study comparing single-agent olaparib, single-agent cediranib, and the combinations of cediranib/olaparib, olaparib/durvalumab (MEDI4736), cediranib/durvalumab (MEDI4736), and olaparib/AZD5363 (capivasertib) in women with recurrent, persistent, or metastatic endometrial cancer.
B.J. Rimel, David Bender, Danielle Enserro, Shannon N. Westin, Debra L. Richardson, Laura L. Holman +9 more
2023· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
1
citations

How this was built: Screen · Findings · About